Publication date: Available online 20 September 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Joshua Richter, Sundar JagannathAbstractOver the last decade the survival outcomes in Multiple Myeloma (MM) have dramatically improved thanks to not only the advent of a number of novel therapies; but also, to the deepening insight regarding how to best utilize these options. Triplet-based induction regimens can yield overall response rates of up to 100%. In the relapsed and refractory setting, we have a multitude of doublet and triplet options with high and durable response rates. The addition of monoclonal antibodies has added a new class of agents to augment our standard approach with novel therapies. Minimal residual disease status testing has worked its way into the lexicon of ...
MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2xF1SVN
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.